A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
Key facts
- Who runs it
- Janssen Research & Development, LLC
- Where
- Atlanta, Austin, Beaumont, Chicago, Cincinnati, Cleveland, Creve Coeur, East Greenwich, Evansville, Huntsville, Knoxville, Lexington, Melbourne, Miami, Mobile, Newton, Peoria, San Diego, Savannah, Walnut Creek, Wichita, and Wilmington, United StatesSee the 24 sitesAlso in 3 other countries, 17 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 959 people enrolled
- Started
- 24 Oct 2023
- Ended
- 26 Jul 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- ExPEC9V
- Placebo
- HD quadrivalent influenza vaccine
- Record updated
- 3 April 2026
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Must be medically stable at the time of vaccination such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol specified follow-up. A stable medical condition is defined as disease not requiring significant change in therapy during the 6 weeks before enrollment and when hospitalization for worsening of the disease is not anticipated. Participants will be included on the basis of physical examination, medical history, and vital signs performed between informed consent form (ICF) signature and vaccination
- Participant must be: a) postmenopausal (postmenopausal state is defined as no menses for 12 months without an alternative medical cause); and b) not intending to conceive by any methods
- Must sign an ICF indicating that the participant understands the purpose, procedures and potential risks and benefits of the study, and is willing to participate in the study
- Willing and able to adhere to the lifestyle restrictions specified in this protocol
- Agrees to not donate blood from the time of vaccination until 3 months after receiving the last dose of study vaccine
Who cannot take part
- History of severe allergic reactions (for example anaphylaxis) to any component of the high-dose (HD) quadrivalent seasonal influenza vaccine, including egg protein, or following a previous dose of any influenza vaccine
- Has had major surgery (per the investigator's judgment) within 4 weeks before administration of the first study vaccine or will not have recovered from surgery per the investigator's judgment at time of vaccination
- History of an underlying clinically significant acute or uncontrolled chronic medical condition or significant cognitive impairment or physical examination findings for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
- Known or suspected allergy or history of severe allergic reaction, anaphylaxis, or other serious adverse reactions to vaccines or vaccine excipients
- History of acute polyneuropathy (for example, Guillain-Barré syndrome) or chronic inflammatory demyelinating polyneuropathy
Where in United States
Also in 3 other countries, 17 sites
- Atlanta Center for Medical ResearchAtlanta, United States
- Benchmark Clinical Research - AustinAustin, United States
- Optimal ResearchAustin, United States
- Tekton Research Inc.Beaumont, United States
- Synexus Clinical Research US, IncChicago, United States
- CTI Clinical Trial and Consulting ServicesCincinnati, United States
- Velocity Clinical ResearchCleveland, United States
- Synexus Clinical Research US IncCreve Coeur, United States
- Velocity Clinical ResearchEast Greenwich, United States
- Synexus Radiant Research, IncEvansville, United States
- Medical Affiliated Research Center Inc. (MARC)Huntsville, United States
- Alliance for Multispeciality ResearchKnoxville, United States
- Alliance for Multispeciality ResearchLexington, United States
- Optimal ResearchMelbourne, United States
- Pharmax Research Clinic IncMiami, United States
- Suncoast Research Associates, LLCMiami, United States
- Alliance for Multispeciality ResearchMobile, United States
- Heartland Research Associates, LLCNewton, United States
- Optimal ResearchPeoria, United States
- Artemis Institute for Clinical ResearchSan Diego, United States
- Velocity Clinical ResearchSavannah, United States
- Diablo Clinical Research, Inc.Walnut Creek, United States
- Heartland Research Associates, an AMR CompanyWichita, United States
- AccellacareWilmington, United States
About the trial
What the trial wants to find out
The purpose of this study is to show that high-dose quadrivalent seasonal influenza vaccine (HD QIV) given together with 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) does not induce lower antibody response against each of the 4 influenza vaccine strains, as compared to HD QIV given alone and further show that ExPEC9V given together with HD QIV does not induce lower antibody response against each of the vaccine O-serotype antigens, as compared to ExPEC9V given alone.
The 2 groups in the trial
- Group 1: Coadministration (CoAd) GroupTreatment being tested
Participants will receive intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) along with high-dose (HD) quadrivalent influenza vaccine, concomitantly, on Day 1 and placebo on Day 30.
Treatment: ExPEC9V, Placebo, and HD quadrivalent influenza vaccine
- Group 2: Control GroupTreatment being tested
Participants will receive IM injection of matching placebo along with HD quadrivalent influenza vaccine, concomitantly, on Day 1 and ExPEC9V on Day 30.
Treatment: ExPEC9V, Placebo, and HD quadrivalent influenza vaccine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
- Record updated
- 3 April 2026